Navigation Links
Pharmatek's Highly-Potent and Cytotoxic (HP/C) Facility Positions It as Industry Leader in Development and Manufacturing of HP/C Compounds
Date:5/5/2009

Pharmatek Demonstrates Effectiveness Of New Highly-Potent And Cytotoxic (HP/C) Facility Through Airborne Particulate Testing.

SAN DIEGO, May 5 /PRNewswire/ -- Pharmatek Laboratories, Inc. - a premier pharmaceutical chemistry development organization supporting the pharmaceutical industry - has completed comprehensive airborne particulate testing of its new state-of-the-art facility for the development and manufacturing of highly-potent and cytotoxic compounds.

"The testing results of our HP/C facility allows Pharmatek to expand our development and manufacturing services to include highly potent and cytotoxic compounds, and do it in the safest possible way," says Tim Scott, President of Pharmatek Laboratories. "The results from extensive facility testing exceeded Pharmatek's expectations for the safe handling of category 4 compounds on a 5 band scheme."

The monitoring results exceeded the testing goals and demonstrate Pharmatek's engineering controls and practices are effective at controlling airborne particulates down to 0.1ug/m3 levels.

"Combined with the facility engineering controls, significantly lower particulate levels are achieved when respiratory protection factors and process specific enclosure systems are taken into account. The specific operator breathing zone results, on an actual time-weighted basis, demonstrate that Pharmatek can safely handle highly-potent and cytotoxic compounds," says Kevin Rosenthal, Director of Manufacturing at Pharmatek Laboratories.

The facility was specifically designed for the development and manufacturing of HP/C drug products. The dedicated facility includes 18,000 sq. ft. of analytical, formulation development and manufacturing lab space. In addition to the development space, there are two certified and validated high-containment manufacturing suites designed with soft-wall enclosure systems that give flexibility to meet the demands of each client's project.

About Pharmatek Laboratories, Inc.

Pharmatek Laboratories Inc. is a pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, and stability storage and testing.

Statements contained in this media release which are not historical facts may constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ from those projected including sales forecasts and strategic expansion. The trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry and Pharmatek Formulation Screening are all property of Pharmatek Laboratories, Inc. Additional information about Pharmatek Laboratories may be obtained at the Web site http://www.pharmatek.com or by calling 858-805-6383.

    Company Contact:
    Ryan Lane, Marketing Coordinator
    Pharmatek Laboratories, Inc.
    (858) 805-6383 x284
    rlane@pharmatek.com

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Jeffrey A. Bibbs

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=48157

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Timothy M. Scott

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=50335


'/>"/>
SOURCE Pharmatek Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
3. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
4. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
5. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
6. Isogen Launches Major New Facility to Address Global Biopharma Demand
7. Micromet Expands Committed Equity Financing Facility to $75 Million
8. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
9. U.S. Meat Industry Will Respond to World Cancer Research Fund Report
10. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
11. EntreMed to Present at The New York Society of Security Analysts Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):